Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of patients with advanced non–small-cell lung cancer (NSCLC) by demonstrating significantly better outcomes and tolerability than conventional chemotherapy. Read More ›